PCWG4 Updates Prostate Cancer Trial Framework: PSMA PET, Molecular Biomarkers, and Patient-Centered Endpoints
PCWG4 revises prostate cancer trial design: integrates PSMA PET/CT for eligibility and response, redefines radiographic progression, and introduces 'no longer clinically benefitting' to guide treatment continuation beyond standard endpoints.

